Regencell Bioscience Holdings
RGC • NASDAQ
Regencell Bioscience Holdings is a drug manufacturers - specialty & generic company in the healthcare sector trading on NASDAQ, led by CEO Yat-Gai Au, with a market cap of $12.7B.
CEOYat-Gai Au
Market Cap$12.7B
Drug Manufacturers - Specialty & Generic
Healthcare
Employees12.0
Websiteregencellbioscience.com
Next Earnings
Upcoming earnings announcement for Regencell Bioscience Holdings
Date
Monday, June 29, 2026 (in 3 months)
Timing
Before Market Open (9:00 AM New York)
Fiscal Period
H1 2026
Earnings History
Past 12 earnings reports for Regencell Bioscience Holdings
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Feb 10, 2026 | FY 2025 | — | — | — | — | — |
| Jun 30, 2025 | H1 2025 | -$0.36 | — | - | — | — |
| Oct 25, 2024 | FY 2024 | -$0.33 | — | - | — | — |
| Jun 20, 2024 | H1 2024 | -$0.16 | — | - | — | — |
| Oct 27, 2023 | FY 2023 | -$0.45 | — | - | — | — |
| Jun 15, 2023 | H1 2023 | -$0.25 | — | - | — | — |
| Oct 31, 2022 | FY 2022 | -$0.58 | — | - | — | — |
| Oct 24, 2017 | Q3 2017 | $0.07Est: $0.06 | +16.7% | $716.0MEst: $709.0M | +1.0% | — |
| Jul 26, 2017 | Q2 2017 | $0.16Est: $0.18 | -11.1% | $764.2MEst: $764.3M | -0.0% | — |
| Apr 26, 2017 | Q1 2017 | $0.32Est: $0.26 | +23.1% | $821.2MEst: $781.0M | +5.2% | — |
| Feb 9, 2017 | Q4 2016 | $0.33Est: $0.26 | +26.9% | $812.6MEst: $801.4M | +1.4% | — |
| Oct 27, 2016 | Q3 2016 | $0.29Est: $0.26 | +11.5% | $811.5MEst: $794.3M | +2.2% | — |